Discontinuing a compound is always a letdown, but it’s much better to find a safety problem in phase-1 than later on.
ENTA will need to find a second oral compound to complement EDP-514 (the lead HBV compound), which could either be another RNA destabilizer or a compound with a different MoA. The company’s drug-discovery engine is up to the task, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.